Reports 2025 revenue $5.8M, consensus $4.82M. “2026 is about building a steady cadence of biopsies and treatments,” said CEO Vish Seshadri. “We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Options Volatility and Implied Earnings Moves This Week, March 16 – March 20, 2026
- ABEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Early ZEVASKYN Launch Traction and Robust Reimbursement Support Abeona Buy Rating and $20 Target
- Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access
- Abeona Therapeutics provides business update on momentum in Zevaskyn launch